CD38 and plasma cell myeloma: In addition to the incorporation of anti-CD38 antibodies into standard of care, CAR-T cell therapy and bispecific T-cell engaging antibodies have emerged as particularly promising treatments poised to define a new wave of myeloma-directed therapeutics.